Search

Displaying results 3581 - 3590 of 10000 in total
  1. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior … It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax.

  2. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril can also be used in hemodialysis patients without risk of serious accumulation. … Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [A225721,A225741] Tirbanibulin blocks the molecular pathways that promote the proliferation, survival, and metastasis of malignant cells.

  4. Drug

    Bexarotene

    go.drugbank.com/drugs/DB00307
    ApprovedInvestigational

    Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

  5. Drug

    Thimerosal

    go.drugbank.com/drugs/DB11590
    Approved

    Although thimerosal is banned in several countries, it continues to be included as a preservative in some vaccines in the United States and many vaccines in the developing world [L1685]. … There has been significant concern regarding its safety and toxicity in the last several decades.

  6. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. … The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018.

  7. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.

  8. Drug

    Perphenazine

    go.drugbank.com/drugs/DB00850
    ApprovedInvestigational

    An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Linoleic acid

    go.drugbank.com/drugs/DB14104
    Approved

    Mixtures: Dr.Different VITAACNAL TX Capsule Serum, Huile D'onagre Vitamin E
  10. Drug

    Diethylcarbamazine

    go.drugbank.com/drugs/DB00711
    ApprovedInvestigationalVet approvedWithdrawn

    An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.